| Absence of relevant cytopenia in the PB |
Relevant cytopenia in the PB for at least 4 months* |
No evidence of morphologic criteria for any hematologic neoplasm;
especially, no dysplasia or blast increase.
PNH, MGUS, and MBL excluded |
MDS-criteria not fulfilled: Dysplasia < 10%, no ring sideroblasts, no blast
increase, no MDS-defining cytogenetic alterations. |
| Evidence of a somatic mutation that is associated with a hematologic neoplasm with a VAF of at least 2% (evidence of clonality) |
| Annual risk of progression to hematologic neoplasm <0.5-1% |
Annual risk of progression to hematologic neoplasm >0.5-1% |